NOXO Autism Balm recommended for use with ADD, ADHD, and Down Syndrome

Healthcare & Pharmaceutical

Share Tweet

NOXO Autism Balm recommended for use with ADD, ADHD, and Down Syndrome

Philadelphia, PA - (Accesswire) -Olfactory Biosciences Corp. (OLFC) the makers of NOXO Autism Balm(TM) are pleased to announce today the professional recommendation for their innovative Autism balm(TM) for use with children and adults that experience sensory irritants.

Dr. V. Ruth Pinney’s formula was designed to lessen theimpact of sensory irritations that trigger overstimulation acting out behaviors. Because it is a sensory aid it will provide a calming effect on those impacted by ADD, ADHD, Down syndrome, fragile X, prematurity and fetal alcohol syndrome.

An excited parent sent this feedback. "Hi  (OLFC), my son takes Concerta for attention deficit disorder. He took the autism balm to school with him and did not take his medication. He described his first day of this as amazing. . . . The autism product clearly worked. He commented about having no side effects such as appetite, mood swings and what I see as simply not being himself when medicated. If this product works for the attention deficit (ADD) population of the world it is a true gift. I am awaiting results from another friend of his with the similar problems. I have another friend with an autistic child that will being receiving the product. My wife and I are excited about our son's experience." Greg

NOXO Autism Balm(TM) is similar to a lip balm but is applied just below thenostrils on the upper lip. Allowing the natural formula to be inhaled and take effect. NOXO’s solution is safe, easy to apply and non-invasive. It works on your body’s natural processes and responses. It is the first product to address behavioral issues triggered by sensitivities.

About Olfactory Biosciences Corp Olfactory Biosciences Corp.’s NOXO division is focused to develop a variety of products targeting Olfactory Receptors for the desired effect. These alternative medicine wellness products may modify behavior or provide relief to common behavior challenges such as anxiety, smoking or weight control, as examples.

You can get more information on NOXO Autism Balm(TM) at


"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements by the Company, statements regarding the NOXO product line, optimism related to the business, expanding ales and other statements in this press release are forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Such statements are based on current expectations, estimates and projections about the Company's business. Words such as expects, anticipates, intends, plans, believes, sees, estimates and variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future performance and involve certain risks and uncertainties that are difficult to predict. Actual results could vary materially from the description contained herein due to many factors including continued market acceptance of the Company's products or the need to raise additional capital. In addition, actual results could vary materially based on changes or slower growth in the indoor garden market; the potential inability to realize expected benefits and synergies; domestic and international business and economic conditions; changes in customer demand or ordering patterns; changes in the competitive environment including pricing pressures or technological changes; technological advances; shortages of manufacturing capacity; future production variables impacting excess inventory and other risk factors listed from time to time in the Company's Securities and Exchange Commission (SEC) filings under "risk factors" and elsewhere. The forward-looking statements contained in this press release speak only as of the date on which they are made, and the Company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this press release.

Richard Stevenson,

Olfactory Biosciences Corp.

333 E. Lancaster Ave. Suite 317

Wynnewood, PA 19096, USA

Phone: 484-278-1626
Source: Olfactory Biosciences Corp.